Table 1. Participant demographics and medications.
| Sex | Age (yrs.) | Genetic subtype | Duration of BL (months) | Duration of Active (months) | Medication | |
|---|---|---|---|---|---|---|
| 003 | M | 24.0 | delPWS | 8 | 12 | Beclometasone nasal, 50mcg, BD Sodium cromoglicate eye drop, 2%, QDS Somatotropine injection, 0.4mg, NOCTE Fexofenadine, 180mcg, OM Risperidone, 1mg, 18:00 |
| 005 | M | 23.11 | delPWS | 10 | 12 | Fluoxetine, 40mg, 08:00 Lamotrigine, 2x 25mg, 08:00 & 18:00 *Lorazepam, 2x 1mg, PRN |
| 009 | M | 41.3 | delPWS | 5 | 12 | Duolexetine, 30mg, 17:00 Quetiapine, 25mg, PM Risperidone, 2x .125ml, AM & PM |
| 010 | F | 23.8 | delPWS | 5 | 12 | Keppra, 2x 500mg, AM & PM Metformin, 2g, PM Forxiga, 10mg, PM Atorvastatin, 20mg, daily Gliclazide, 40mg, 2x AM & 1x PM |
| 011 | F | 21.8 | delPWS | 5 | 12 | Vitamin D, 1000 units, daily Somatotropin, 1.2mg, PM Loestrin 20, x1, daily for 21 days then 7 day break |
Age (years. months) at first day of baseline; delPWS, paternal interstitial deletion; BL, baseline phase; month, 30 days; Medication, name, dosage, time administered.
* change in medication at day 84 of 246 baseline phase.